111 related articles for article (PubMed ID: 28090373)
1. hGBP-1 Expression Predicts Shorter Progression-Free Survival in Ovarian Cancers, While Contributing to Paclitaxel Resistance.
Wadi S; Tipton AR; Trendel JA; Khuder SA; Vestal DJ
J Cancer Ther; 2016 Dec; 7(13):994-1007. PubMed ID: 28090373
[TBL] [Abstract][Full Text] [Related]
2. Guanylate-Binding Protein-1 protects ovarian cancer cell lines but not breast cancer cell lines from killing by paclitaxel.
Tipton AR; Nyabuto GO; Trendel JA; Mazur TM; Wilson JP; Wadi S; Justinger JS; Moore GL; Nguyen PT; Vestal DJ
Biochem Biophys Res Commun; 2016 Sep; 478(4):1617-23. PubMed ID: 27590579
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of cathepsin L sensitizes ovarian cancer cells to chemotherapy.
Zhang H; Zhang L; Wei L; Gao X; Tang LI; Gong W; Min NA; Zhang LI; Yuan Y
Oncol Lett; 2016 Jun; 11(6):4235-4239. PubMed ID: 27313771
[TBL] [Abstract][Full Text] [Related]
4. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of UTP23 promotes paclitaxel resistance and predicts poorer prognosis in ovarian cancer.
Fu Z; Wang C; Chen Y; Zhang X; Wang X; Xie X
Pathol Res Pract; 2019 Nov; 215(11):152625. PubMed ID: 31540773
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Cathepsin L is associated with chemoresistance and invasion of epithelial ovarian cancer.
Sui H; Shi C; Yan Z; Wu M
Oncotarget; 2016 Jul; 7(29):45995-46001. PubMed ID: 27351223
[TBL] [Abstract][Full Text] [Related]
7. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
9. The human guanylate-binding proteins hGBP-1 and hGBP-5 cycle between monomers and dimers only.
Ince S; Kutsch M; Shydlovskyi S; Herrmann C
FEBS J; 2017 Jul; 284(14):2284-2301. PubMed ID: 28580591
[TBL] [Abstract][Full Text] [Related]
10. Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines.
Chen M; Huang H; He H; Ying W; Liu X; Dai Z; Yin J; Mao N; Qian X; Pan L
Cancer Sci; 2015 Aug; 106(8):1075-83. PubMed ID: 26033570
[TBL] [Abstract][Full Text] [Related]
11. Homo and hetero dimerisation of the human guanylate-binding proteins hGBP-1 and hGBP-5 characterised by affinities and kinetics.
Kutsch M; Ince S; Herrmann C
FEBS J; 2018 Jun; 285(11):2019-2036. PubMed ID: 29618166
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.
Zhang X; Feng Y; Wang XY; Zhang YN; Yuan CN; Zhang SF; Shen YM; Fu YF; Zhou CY; Li X; Cheng XD; Lu WG; Xie X
Cell Death Dis; 2018 Jan; 9(2):93. PubMed ID: 29367628
[TBL] [Abstract][Full Text] [Related]
13. Understanding the lower GMP formation in large GTPase hGBP-2 and role of its individual domains in regulation of GTP hydrolysis.
Rajan S; Pandita E; Mittal M; Sau AK
FEBS J; 2019 Oct; 286(20):4103-4121. PubMed ID: 31199074
[TBL] [Abstract][Full Text] [Related]
14. Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells.
Lee DH; Chung K; Song JA; Kim TH; Kang H; Huh JH; Jung SG; Ko JJ; An HJ
J Proteome Res; 2010 Nov; 9(11):5668-76. PubMed ID: 20858016
[TBL] [Abstract][Full Text] [Related]
15. [Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].
Guo YQ; Lu P; Duan ZF; Zhang Z
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):854-9. PubMed ID: 21211286
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-2'-Ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity.
Tanino T; Nawa A; Kondo E; Kikkawa F; Daikoku T; Tsurumi T; Luo C; Nishiyama Y; Takayanagi Y; Nishimori K; Ichida S; Wada T; Miki Y; Iwaki M
Pharm Res; 2007 Mar; 24(3):555-65. PubMed ID: 17245652
[TBL] [Abstract][Full Text] [Related]
17. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57.
Cicchillitti L; Di Michele M; Urbani A; Ferlini C; Donat MB; Scambia G; Rotilio D
J Proteome Res; 2009 Apr; 8(4):1902-12. PubMed ID: 19714814
[TBL] [Abstract][Full Text] [Related]
18. Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line.
Gao JH; He ZJ; Wang Q; Li X; Li YX; Liu M; Zheng JH; Tang H
Chin Med J (Engl); 2008 Aug; 121(16):1563-8. PubMed ID: 18982869
[TBL] [Abstract][Full Text] [Related]
19. Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells.
Britten RA; Perdue S; Eshpeter A; Merriam D
Oncol Rep; 2000; 7(4):821-5. PubMed ID: 10854551
[TBL] [Abstract][Full Text] [Related]
20. Biological characteristics of Taxol‑resistant ovarian cancer cells and reversal of Taxol resistance by adenovirus expressing p53.
Liu Q; Sui R; Li R; Miao J; Liu J
Mol Med Rep; 2015 Feb; 11(2):1292-7. PubMed ID: 25351378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
